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Abstract There is a lack of data regarding the incidence
and clinical signiﬁcance of apnoea or bradycardia (AB)
following immunisation with combination vaccines
containing an acellular pertussis (Pa) component in
respiratory stable preterm infants. Medical records of
respiratory stable preterm infants who received a ﬁrst
dose of a combined diphtheria (D) and tetanus (T)
toxoids, Pa, Haemophilus inﬂuenzae type b (Hib),
inactivated poliovirus (IPV) vaccine with or without
hepatitis B virus (HBV) in the neonatal intensive care
unit (NICU) of the University Children’s Hospital Basel
between January 2000 and June 2003 were analysed. For
each infant, clinical data were recorded for a 72 h period
before and after immunisation. Of 53 infants with a
mean gestational age of 28 weeks, 7 (13%) showed a
transient recurrence of or increase in episodes of AB
following immunisation. Five of these seven infants re-
quired intervention ranging from tactile stimulation to
bag and mask ventilation. Regarding risk factors, chil-
dren with recurrent or increased AB were indistin-
guishable from those without such events. The rate of
fever (>38C) following immunisation was higher in
aﬀected infants compared to those without recurrence of
or increase in AB (3/7 vs 2/46, P =0.01). Conclusion:
Although most infants tolerated immunisation well, the
incidence of recurrent or increased apnoea or brady-
cardia in respiratory stable preterm infants following the
ﬁrst immunisation with penta- or hexavalent vaccines
was 13%. Most apnoea or bradycardia events required
intervention but did not have serious consequences.
Monitoring of all preterm infants following immunisa-
tion in the neonatal intensive care unit is recommended.
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Introduction
Oﬃcial guidelines in North America, Australia and
various European countries recommend immunising
stable preterm infants at the same chronological age as
full-term infants because of their increased risk of vac-
cine-preventable diseases and suﬃcient immune re-
sponses. Concerns have been raised after the recognition
of clinically signiﬁcant apnoea following the immunisa-
tion of hospitalised preterm infants with diphtheria (D),
tetanus (T), whole cell pertussis (Pw), and Haemophilus
inﬂuenzae type B (Hib) component vaccines [2, 8,9].
Recent studies have shown similar cardiorespiratory
events after administration of combination vaccines
containing an acellular pertussis (Pa) component in co-
horts of former preterm infants with a large proportion
of infants on respiratory support or supplemental oxy-
gen at the time of immunisation, both known to be risk
factors for post-immunisation apnoea [3, 6,10]. We re-
port on the incidence and clinical signiﬁcance of post-
immunisation apnoea or bradycardia (AB) in former
preterm infants not requiring respiratory support or
supplemental oxygen and immunised with a pentavalent
(DTPa-IPV/Hib) or hexavalent vaccine (DTPa-IPV-
HBV/Hib) in the neonatal intensive care unit (NICU).
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Subjects and methods
Medical records of all preterm infants, hospitalised for
at least 8 weeks after birth, who had received their ﬁrst
Infanrix DTPa-IPV+Hib or Infanrix Hexa (containing
DTPa-IPV+Hib+HBV) vaccine (GlaxoSmithKline,
Rixensart, Belgium) between January 2000 and June
2003 in the NICU of the University Children’s Hospital,
Basel, Switzerland, were analysed retrospectively.
Apnoea was deﬁned as ‡20 s without breathing, and
bradycardia as a heart rate <100/min for at least 20 s
according to our general institutional guidelines for the
monitoring of preterm infants. All 60 identiﬁed infants
had a previous history of typical AB of prematurity. A
total of 53 infants were continuously monitored by
electrocardiogram and chest wall impedance monitors.
Six infants were monitored by pressure sensors only and
one infant was without technical monitoring for un-
known reasons; the latter seven patients were excluded
from the analysis.
Infants were considered to have recurrent or in-
creased AB after immunisation when recurrence of or a
‡50% increase in the frequency of AB episodes occurred
in the 72 h period following immunisation compared to
the 72 h period preceding immunisation. Bronchopul-
monary dysplasia was deﬁned as a need for supple-
mental oxygen at 36 weeks postmenstrual age or at a
chronological age of 4 weeks to maintain an oxygen
saturation of at least 88%.
At the time of immunisation, all infants were medi-
cally stable and did not require any ventilatory support
or continuous supplemental oxygen. Rectal temperature
was measured routinely every 8 h and in addition when
nursing staﬀ suspected fever. Children with recurrent or
increased AB were compared with those without such
events in order to identify possible predictive factors.
Statistical analysis was performed by the Prism 4 for
Mac OS X software package (GraphPad Software, San
Diego, USA) using the Student t -test, Mann-Whitney
test and Fisher’s exact test as appropriate.
Results
In the 72 h control period before immunisation, 16 in-
fants had AB (median 3 episodes, range 1 to 19). In this
period, no infant with AB required any intervention. In
the 72 h period following immunisation, seven infants
(13%) had recurrent or increased AB (median 6 epi-
sodes, range 2 to 33) (Fig. 1). Episodes started 8 to 24 h
after and settled within 48 h following immunisation.
Five infants required repeated tactile stimulation and
three of them needed supplemental oxygen. One infant
additionally needed resuscitation by brief bag and mask
ventilation because of prolonged AB and hypoxaemia.
No infant required restart of caﬀeine treatment, con-
tinuous positive airway pressure (CPAP), or re-intuba-
tion. Infants showing recurrent or increased episodes of
AB were indistinguishable from those without recur-
rence of or increase in AB (Table 1). A comparison
between the proportion of hexavalent and pentavalent
vaccinations in both groups revealed no diﬀerence
regarding recurrence of or increase in AB (2/7 vs. 12/46,
P =1.0). The rate of fever (>38C) following immuni-
sation was higher in the group of apnoeic infants com-
pared to those without recurrence of or increase in AB
(3/7 vs. 2/46, P =0.01). There were no signs of late
onset sepsis or intercurrent infection in infants who had
fever following immunisation.
Discussion
The incidence of apnoea in hospitalised preterm infants
following immunisation with DTPw-Hib combination
vaccines has been reported to be in the range of 7% to
23% [2, 8,9]. Studies reporting no increased risk of ap-
noea in preterm infants after the ﬁrst DTPw vaccination
were based on parents’ diaries in outpatient settings
[1,7]. In such settings without monitoring, however, it
may be diﬃcult to recognise apnoea.
Recent studies showed that the use of vaccines
incorporating Pa instead of Pw vaccine components
does not prevent post-immunisation apnoea in former
preterm infants, thus making it very unlikely to suspect
endotoxin as an important trigger factor for these
events, because Pa does not contain endotoxin [3,10].
The cause of AB after immunisation is not yet identiﬁed,
and it has been speculated that it might be an unspeciﬁc
CNS reaction to vaccine-induced stimulation of the
immune system [5]. The delay between immunisation
and onset of AB was between 8 and 24 h and is in
agreement with this hypothesis. Similarly, the onset of
fever as a side-eﬀect after immunisation with pertussis
component and other killed vaccines usually also occurs
after 6 to 24 h [11]. It is therefore tempting to assume
that similar underlying immunological mechanisms are
responsible for these observations.
Fig. 1 Individual numbers of AB episodes in seven preterm infants
after their ﬁrst combined immunisation
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Major risk factors for post-immunisation apnoea in
the above-mentioned studies were mechanical ventila-
tion, CPAP or continuous supplemental oxygen at the
time of immunisation [3, 6,10]. The authors reported an
incidence of 13% and 38%, respectively, of post-im-
munisation apnoea, the diﬀerence probably partly being
due to diﬀerent deﬁnitions of increased apnoea [3,10].
Our ‘‘low risk’’ study population entirely consisted of
infants without respiratory support or supplemental
oxygen at the time of immunisation. There was a 13%
incidence of recurrent or increased AB in these infants
using a relatively rigid deﬁnition of ‘‘increase in AB’’.
However, reporting bias cannot be excluded as nursing
staﬀ documenting AB were aware of the time of im-
munisation. While recent data from Pﬁster and col-
leagues [6] strongly suggests that a severe clinical
condition at 8 weeks of age and the persistence of pre-
maturity-associated AB during the 24 h preceding im-
munisation increases the risk of post-immunisation AB
in former preterm infants 5- to 8-fold, it is still advisable
to monitor stable preterm infants following immunisa-
tion in the NICU, because the majority of events in our
‘‘low risk’’ population transiently required mild to
moderate interventions. We detected an increased rate of
fever in the group of apnoeic infants, therefore addi-
tional temperature monitoring might be helpful in
identifying infants at risk of recurrent or increased AB.
Regarding risk factors, the retrospective design and
small sample size of our study does not allow to draw
ﬁrm conclusions from the fact that we found no speciﬁc
risk factors predisposing infants to post-immunisation
AB.
Prophylaxis for AB after the ﬁrst immunisation of
preterm infants is not established. The use of methylx-
anthines could be helpful as shown for the prevention of
postoperative apnoea in preterm infants undergoing
general anaesthesia for minor surgery [4], but there is no
such study for post-immunisation apnoea yet. Further-
more, there is no data available on the safety of the
second combined immunisation. It remains unclear if
some former extremely low birth weight infants might
have cardiorespiratory events in this situation.
In conclusion, most preterm infants tolerated the
ﬁrst immunisation well. There was a 13% risk of
developing post-immunisation AB with combination
vaccines containing a Pa component in preterm infants
not needing mechanical ventilation, CPAP or supple-
mental oxygen; most events required clinical interven-
tion ranging from tactile stimulation to brief bag and
mask ventilation, but they were all transient and
without severe consequences on the clinical course. The
beneﬁt of timely administration of immunisation in
former preterm infants by far outweighs the risk of
post-immunisation AB. Monitoring of previously
respiratory stable preterm infants for 48 h after their
ﬁrst standard immunisation is justiﬁed.
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Table 1 Basic characteristics
and clinical conditions of
respiratory stable preterm
infants with or without AB
following immunisation
aUnpaired Student t -test
bMann-Whitney U-test
cFisher’s exact test
Recurrence of
or increase in AB
( n =7)
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( n =46)
P
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